About
Articles by Errik
-
We’re Here to Help: You Can Wait to Pay Alloy for Your Drug Discovery Work
We’re Here to Help: You Can Wait to Pay Alloy for Your Drug Discovery Work
By Errik Anderson
-
Celebrating 100 Partners in the Alloy Biotechnology Ecosystem
Celebrating 100 Partners in the Alloy Biotechnology Ecosystem
By Errik Anderson
Activity
-
Our portfolio company HI-Bio announced it is being acquired by Biogen for up to $1.8B. Warm congratulations to colleagues Travis Murdoch, MD and…
Our portfolio company HI-Bio announced it is being acquired by Biogen for up to $1.8B. Warm congratulations to colleagues Travis Murdoch, MD and…
Liked by Errik Anderson
-
A huge congratulations to my partner Christian Kanady, who has been an amazing investor and co-founder at Wheeler Bio, Inc. Christian and the Echo…
A huge congratulations to my partner Christian Kanady, who has been an amazing investor and co-founder at Wheeler Bio, Inc. Christian and the Echo…
Shared by Errik Anderson
-
I’m happy to share that I’m starting a new position as Head of Antibody Discovery US Large Molecule Research at Sanofi!
I’m happy to share that I’m starting a new position as Head of Antibody Discovery US Large Molecule Research at Sanofi!
Liked by Errik Anderson
Experience & Education
Volunteer Experience
-
Member of the Board of Advisors
The Tuck School of Business at Dartmouth
- Present 3 years 1 month
Education
-
Magnuson Center for Entrepreneurship - Advisory Board Member
Dartmouth College
- Present 6 years 4 months
Education
-
Patents
-
Recombinant prokaryotes and use thereof for production of O-glycosylated proteins
Issued US 9051593
The present invention embraces a recombinant prokaryotic host cell containing nucleic acids encoding an eukaryotic UDP-GaINAc:UDP-GaINAc polypeptide transferase and expressing an UDP-GIcNAc C-4 epimerase and methods for using the same to produce an O-glycosylated protein.
Other inventorsSee patent
More activity by Errik
-
I'm thrilled to share that in this tough market environment we secured a $90M Series C to advance our first-in-class PD1-IL18 immunoconjugate BPT567…
I'm thrilled to share that in this tough market environment we secured a $90M Series C to advance our first-in-class PD1-IL18 immunoconjugate BPT567…
Liked by Errik Anderson
-
I am humbled and honored to be recognized by Boston Magazine as one of the 150 Most Influential Bostonians. I am proud to live in a city and work for…
I am humbled and honored to be recognized by Boston Magazine as one of the 150 Most Influential Bostonians. I am proud to live in a city and work for…
Liked by Errik Anderson
-
Official PR coming soon, but I’m thrilled that CrossBridge Bio’s CPRIT SEED for our TROP2 Dual Payload ADC was funded! Top score to boot! We’re…
Official PR coming soon, but I’m thrilled that CrossBridge Bio’s CPRIT SEED for our TROP2 Dual Payload ADC was funded! Top score to boot! We’re…
Liked by Errik Anderson
-
Totally surprised and delighted to receive the award of Life Honourary Membership of the Society of Construction Law from Lord Justice Coulson on 1…
Totally surprised and delighted to receive the award of Life Honourary Membership of the Society of Construction Law from Lord Justice Coulson on 1…
Liked by Errik Anderson
-
We are excited to announce a broad license agreement with Eli Lilly and Company to access Alloy's best-in-class ATX-Gx™ and ATX-CLC™ fully human…
We are excited to announce a broad license agreement with Eli Lilly and Company to access Alloy's best-in-class ATX-Gx™ and ATX-CLC™ fully human…
Liked by Errik Anderson
People also viewed
-
Thomas Schuetz
Connect -
Heather Schwoebel
Connect -
Victor Stone M.D. (石井 喜英)
Connect -
Ryan McGovern
Connect -
Ross P. C.
Connect -
Logan Snyder
Connect -
Carlos Loya
Connect -
Ugur Eskiocak
CEO at Voro Therapeutics | EiR at 82VS/Alloy
Connect -
Russell Beckerman
Connect -
Patrick Bradley
Deputy General Counsel at Alloy Therapeutics
Connect
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More